Total 2 related articles
News/Tag
Lead report
AstraZeneca and Bristol Myers Squibb held early merger talks, per FT.
AstraZeneca (AZN) Q2 results: non-GAAP EPS beats by $1.36 while revenue slightly misses despite 6.4% Y/Y growth.